CLINICAL_TRIALS trial_result · 2024-11-13

Clinical Trial Update: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma [Phase 3]

A Phase 3 trial evaluating E7777 for persistent and recurrent cutaneous T-cell lymphoma has completed. Results from the study have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Eisai Inc. | Conditions: Persistent or Recurrent Cutaneous T-Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2024-11-13